PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China.\', \'Wuhan Institute of Biological Products, Hubei, China.\', \'National Vaccine & Serum Institute, Beijing, China.\', \'Department of Pharmaceutical Engineering, College of Life Science and Technology, Dalian University, Dalian, China.\', \'Graduate School of Peking Union Medical College, Beijing, China.\', \'Department of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, China.\', \'China National Biotec Group Company Limited, Beijing, China.\', \'National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., Wuhan, China.\', \'Translational Medicine Institute, First People\'s Hospital of Chenzhou, University of South China, Chenzhou, China.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.3389/fimmu.2021.687869
?:hasPublicationType
?:journal
  • Frontiers in immunology
is ?:pmid of
?:pmid
?:pmid
  • 34220844
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.803
?:rankingScore_hIndex
  • 69
is ?:relation_isRelatedTo_publication of
?:title
  • The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34220844>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34220844>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all